A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature | Zendy

Dalia Cuenca | Zendy; Mercedes Aguilar-Soto | Zendy; Moisés Mercado | Zendy

Open Access

A Case of Graves’ Disease Following Vaccination with the Oxford-AstraZeneca SARS-CoV-2 Vaccine: Case Report and Review of the Literature

Author(s) -

Dalia Cuenca,

Mercedes Aguilar-Soto,

Moisés Mercado

Publication year - 2022

Publication title -

european journal of case reports in internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.125

H-Index - 1

ISSN - 2284-2594

DOI - 10.12890/2022_003275

Subject(s) - medicine , covid-19 , vaccination , disease , virology , graves' disease , pediatrics , infectious disease (medical specialty) , outbreak

A 57-year-old man presented to the outpatient clinic with tremor, palpitations, weight loss and fatigue 1 week after receiving the first dose of the Oxford-AstraZeneca SARS-CoV-2 vaccine (ChAdOx1 nCoV-19). Laboratory studies showed a suppressed TSH with elevated total and free T4. Thyroid peroxidase and thyroglobulin antibodies were elevated but thyrotropin receptor autoantibodies were indeterminate. Thyroid scintigraphy with technetium Tc-99m pertechnetate revealed increased diffuse, symmetric uptake. The patient was treated with thiamazole 15 mg three times a day and propranolol with resolution of his symptoms and normalization of his thyroid function tests until discontinuation of the antithyroid drug 6 months after symptom onset.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research